DOP2006000141A - Derivados de oxindol - Google Patents

Derivados de oxindol

Info

Publication number
DOP2006000141A
DOP2006000141A DO2006000141A DO2006000141A DOP2006000141A DO P2006000141 A DOP2006000141 A DO P2006000141A DO 2006000141 A DO2006000141 A DO 2006000141A DO 2006000141 A DO2006000141 A DO 2006000141A DO P2006000141 A DOP2006000141 A DO P2006000141A
Authority
DO
Dominican Republic
Prior art keywords
compounds
oxindol derivatives
oxindol
derivatives
eat
Prior art date
Application number
DO2006000141A
Other languages
English (en)
Inventor
Kin-Chun Luk
Sung-Sau So
Jing Zhang
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of DOP2006000141A publication Critical patent/DOP2006000141A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La invencion describe compuestos de la formula general o las sales farmaceuticamente aceptables de los mismos, en la que R1, R2, R4 y R5 tienen los significados definidos en la descripcion, un proceso para su obtencion, medicamentos que los contienen asi como el use de estos compuestos coma agentes farmaceuticamente activos. Estos compuestos presentan actividad como agentes antiproliferante y pueden ser especialmente utiles para el tratamiento del cancer.
DO2006000141A 2005-06-24 2006-06-21 Derivados de oxindol DOP2006000141A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69375205P 2005-06-24 2005-06-24
US79561606P 2006-04-27 2006-04-27

Publications (1)

Publication Number Publication Date
DOP2006000141A true DOP2006000141A (es) 2006-12-31

Family

ID=37114613

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2006000141A DOP2006000141A (es) 2005-06-24 2006-06-21 Derivados de oxindol

Country Status (16)

Country Link
US (1) US7576082B2 (es)
EP (1) EP1896412A2 (es)
JP (1) JP2008543917A (es)
KR (1) KR100990344B1 (es)
CN (1) CN101203489B (es)
AR (1) AR054799A1 (es)
AU (1) AU2006260934B2 (es)
BR (1) BRPI0612535A2 (es)
CA (1) CA2612451A1 (es)
DO (1) DOP2006000141A (es)
IL (1) IL188039A0 (es)
MX (1) MX2007016038A (es)
PA (1) PA8680701A1 (es)
TW (1) TW200728276A (es)
UY (1) UY29633A1 (es)
WO (1) WO2006136606A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007006519D1 (de) 2006-09-21 2010-06-24 Hoffmann La Roche Oxindolderivate als antikrebsmittel
PE20081897A1 (es) 2007-03-29 2009-02-09 Novartis Ag 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
US8455520B2 (en) 2007-07-17 2013-06-04 Merck Sharp & Dohme Corp. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
US7928233B2 (en) * 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
WO2010109008A1 (en) 2009-03-26 2010-09-30 Topotarget A/S Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones
WO2011060049A2 (en) * 2009-11-12 2011-05-19 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
WO2011106650A2 (en) * 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
UA109464C2 (uk) 2010-11-12 2015-08-25 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Спірооксіндольні антагоністи mdm2
US8962828B2 (en) 2010-12-21 2015-02-24 Bayer Intellectual Property Gmbh Method for producing triazinyl-substituted oxindoles
EP2966061B1 (en) 2011-03-04 2017-05-03 Life Technologies Corporation Compounds and methods for conjugation of biomolecules
EP2684880B1 (en) 2011-03-10 2018-02-28 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivative
CA2835422C (en) 2011-05-11 2016-10-11 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
JP6373978B2 (ja) 2013-05-27 2018-08-15 ノバルティス アーゲー イミダゾピロリジノン誘導体および疾患の処置におけるその使用
AU2014272700B2 (en) 2013-05-28 2016-12-01 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
US9624247B2 (en) 2013-05-28 2017-04-18 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
CA2931249A1 (en) 2013-11-21 2015-05-28 Novartis Ag Pyrrolopyrrolone derivatives and their use as bet inhibitors
US9718775B2 (en) 2014-03-14 2017-08-01 Milliken & Company Oxindole compounds and compositions comprising the same
TWI711452B (zh) 2015-02-20 2020-12-01 日商第一三共股份有限公司 癌症的倂用治療法
TWI697329B (zh) 2015-04-13 2020-07-01 日商第一三共股份有限公司 血液癌症治療用之醫藥及其用途
CN113788818A (zh) 2016-04-06 2021-12-14 密执安大学评议会 Mdm2蛋白质降解剂
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
CA3022868A1 (en) 2016-05-02 2017-11-09 Shaomeng Wang Piperidines as menin inhibitors
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
WO2018074387A1 (ja) 2016-10-17 2018-04-26 第一三共株式会社 Ｍｄｍ２阻害剤とｄｎａメチルトランスフェラーゼ阻害剤との併用治療法
MX2019011412A (es) 2017-03-31 2020-02-07 Univ Michigan Regents Piperidinas como inhibidores de menina covalentes.
CN108610277A (zh) * 2018-03-20 2018-10-02 贵州大学 3-叔胺四取代氧化吲哚化合物及其制备方法
CN112912143A (zh) 2018-10-08 2021-06-04 美国密歇根州立大学试剂中心 小分子mdm2蛋白降解剂
TW202200543A (zh) 2020-03-19 2022-01-01 美商凱麥拉醫療公司 Mdm2降解劑及其用途
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN113880750B (zh) * 2021-10-28 2023-02-10 上海交通大学 一种手性3-取代-3-芳基氧化吲哚类化合物的合成方法
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2759935A (en) 1953-02-18 1956-08-21 Bristol Lab Inc Substituted 3-phenyloxindoles
US3441570A (en) 1966-01-20 1969-04-29 Parke Davis & Co 3-tertiary aminoalkylamino-3-phenyl oxindole compounds
US3686210A (en) 1970-01-13 1972-08-22 American Home Prod 2-acylamido-3-aryl-3h-indol-3-ol esters and related compounds
GB1494340A (en) * 1974-12-03 1977-12-07 Wyeth John & Brother Ltd Process for preparation of substituted n-phenylcarbamate esters
US4020179A (en) 1975-05-15 1977-04-26 Richardson-Merrell Inc. 7-Substituted-2-indolinones
JPS55129284A (en) 1979-03-27 1980-10-06 Shionogi & Co Ltd 3-(1-imipazolyl)indolin-2-one
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
JP3748935B2 (ja) * 1996-03-18 2006-02-22 大鵬薬品工業株式会社 オキシインドール誘導体
WO1998002432A1 (en) 1996-07-16 1998-01-22 Takeda Chemical Industries, Ltd. Bicyclic compounds for controlling micturition
WO1998054167A1 (fr) 1997-05-28 1998-12-03 Mitsubishi-Tokyo Pharmaceuticals, Inc. Composes d'indole
US6511974B1 (en) 1997-07-30 2003-01-28 Wyeth Tricyclic vasopressin agonists
JP2000191661A (ja) 1998-12-25 2000-07-11 Mitsubishi-Tokyo Pharmaceuticals Inc 環状アミド化合物
RU2331640C2 (ru) 1999-05-21 2008-08-20 Бристол-Маерс Сквибб Ко. Пирролтриазиновые ингибиторы киназ
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
CA2478172A1 (en) 2002-03-15 2003-09-25 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
JP5125501B2 (ja) 2005-01-28 2013-01-23 大正製薬株式会社 １，３−ジヒドロ−２ｈ−インドール−２−オン化合物、及び芳香族複素環が縮合したピロリジン−２−オン化合物

Also Published As

Publication number Publication date
AU2006260934B2 (en) 2012-03-29
AR054799A1 (es) 2007-07-18
PA8680701A1 (es) 2007-01-17
AU2006260934A1 (en) 2006-12-28
MX2007016038A (es) 2008-03-10
JP2008543917A (ja) 2008-12-04
KR100990344B1 (ko) 2010-10-29
CA2612451A1 (en) 2006-12-28
TW200728276A (en) 2007-08-01
US7576082B2 (en) 2009-08-18
UY29633A1 (es) 2007-01-31
CN101203489B (zh) 2011-08-31
WO2006136606A2 (en) 2006-12-28
US20060293319A1 (en) 2006-12-28
IL188039A0 (en) 2008-03-20
CN101203489A (zh) 2008-06-18
KR20080022117A (ko) 2008-03-10
EP1896412A2 (en) 2008-03-12
BRPI0612535A2 (pt) 2010-11-23
WO2006136606A3 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
DOP2006000141A (es) Derivados de oxindol
ECSP066958A (es) Compuestos de morfolina
UY30282A1 (es) Compuestos quimicos
PE20150998A1 (es) Inhibidores de histona demetilasas
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
UY28955A1 (es) Nuevos derivados fluoroglicosídicos de pirazoles, medicamentos que contienen estos compuestos, y el empleo de los mismos
PA8748101A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
GT200600028A (es) Compuestos y composiciones como inhibidores de proteina kinasa
UY29616A1 (es) Compuestos químicos iii
PA8622401A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico,procesos para su preparacion y su uso como medicamentos
ECSP109934A (es) Compuesto - 946
UY29615A1 (es) Compuestos quimicos iv
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
ECSP088869A (es) Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica
CU20090184A7 (es) Compuestos amino-heterocíclicos
UY29617A1 (es) Compuestos químicos vii
GT200800148A (es) Agente terapéutico para la enfermedad inflamatoria intestinal conteniendo como ingrediente activo un derivado de 2-amino-1,3-propanediol o un método para el tratamiento de la enfermedad inflamatoria intestinal.
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
ATE523495T1 (de) Substituierte pyrazolinverbindungen, deren herstellung und verwendung als medikamente
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
DK2173749T3 (da) 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl)-acetamidderivater og beslægtede forbindelser som antisvampemidler
UY31346A1 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina
UY29790A1 (es) Sales de diariloimidazola-4-carboxamidas, composiciones que las contienen, procesos de preparación y aplicaciones